DPP-IV Inhibitors

DPP-IV Inhibitors

Global DPP-IV Inhibitors Market to Reach US$14.7 Billion by 2030

The global market for DPP-IV Inhibitors estimated at US$13.0 Billion in the year 2023, is expected to reach US$14.7 Billion by 2030, growing at a CAGR of 1.7% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$3.4 Billion While China is Forecast to Grow at 1.7% CAGR

The DPP-IV Inhibitors market in the U.S. is estimated at US$3.4 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 1.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

DPP-IV Inhibitors - Key Trends and Drivers

Dipeptidyl peptidase-4 (DPP-IV) inhibitors are a class of oral hypoglycemic agents used to treat type 2 diabetes mellitus. These inhibitors work by blocking the DPP-IV enzyme, which is responsible for degrading incretin hormones such as glucagon-like peptide-1 (GLP-1). By inhibiting this enzyme, DPP-IV inhibitors increase the levels of incretin hormones, thereby enhancing the secretion of insulin in response to meals and reducing the release of glucagon. This dual action helps to lower blood glucose levels effectively. Commonly prescribed DPP-IV inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin, which are typically used in combination with other antidiabetic medications or as monotherapy when other treatments are not suitable. These drugs have gained popularity due to their efficacy, relatively low risk of hypoglycemia, and oral administration, which is preferred by many patients over injectable therapies.

Several trends and developments are influencing the DPP-IV inhibitors market. One significant trend is the increasing prevalence of type 2 diabetes globally, driven by factors such as aging populations, sedentary lifestyles, and rising obesity rates. This surge in diabetes cases is boosting demand for effective and convenient treatment options like DPP-IV inhibitors. Additionally, ongoing research and development are leading to the introduction of new and improved DPP-IV inhibitors with enhanced efficacy and safety profiles. Pharmaceutical companies are also exploring combination therapies that pair DPP-IV inhibitors with other antidiabetic drugs, such as sodium-glucose co-transporter-2 (SGLT-2) inhibitors and metformin, to provide more comprehensive blood sugar control. Furthermore, there is a growing emphasis on personalized medicine, where treatments are tailored to individual patient profiles based on genetic, environmental, and lifestyle factors. This approach is expected to optimize the effectiveness of DPP-IV inhibitors and minimize adverse effects.

The growth in the DPP-IV inhibitors market is driven by several factors. Technological advancements in drug discovery and development are enabling the creation of more potent and selective DPP-IV inhibitors, improving patient outcomes. The rising global prevalence of type 2 diabetes particularly in emerging economies is expanding the market for these medications. Increasing awareness about diabetes management and the importance of maintaining optimal blood glucose levels is encouraging more patients to seek treatment, boosting demand for DPP-IV inhibitors. Additionally, the convenience of oral administration and the relatively favorable side effect profile of DPP-IV inhibitors are driving their adoption among patients and healthcare providers. Strategic collaborations and partnerships among pharmaceutical companies are also fostering innovation and facilitating the introduction of new products to the market. Furthermore, supportive government policies and reimbursement frameworks in many countries are making these treatments more accessible to a broader patient population, thereby driving market growth.

Select Competitors (Total 16 Featured) -

• AstraZeneca Plc.
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Takeda Pharmaceutical Company Limited

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.